대전과 충청남북도에 거주하는 만성 C형간염 환자에서 페그인터페론 알파 2a와 2b의 초치료 효과 비교
Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study
2
조회
0
다운로드
4
인용
0
참고문헌
초록
Backgrounds/Aims: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C. Methods: Ninety-seven patients were treated with peginterferon alpha-2a (180 µg/week, n=48) or peginterferon alpha-2b (1.5 µg/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively. Results: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peginterferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia. Conclusions: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
Abstract
Backgrounds/Aims: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C. Methods: Ninety-seven patients were treated with peginterferon alpha-2a (180 µg/week, n=48) or peginterferon alpha-2b (1.5 µg/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively. Results: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peginterferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia. Conclusions: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
참고문헌 (18)
- Lauer GM, "Hepatitis C virus infection", N Engl J Med, 345, pp.41~52 (2001)
- Hoofnagle JH, "Peginterferon and ribavirin for chronic hepatitis C", N Engl J Med, 355, pp.2444~2451 (2006)
- McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C", N Engl J Med, 339, pp.1485~1492 (1998)
- Zeuzem S, "Peginterferon alfa-2a in patients with chronic hepatitis C", N Engl J Med, 343, pp.1666~1672 (2000)
- Yoon BC, "Therapeutic efficacy of combination therapy with alpha interferon and ribavirin in chronic hepatitis C", Korean J Gastroenterol, 37, pp.203~209 (2001)
- Lee H, "Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea", Korean J Hepatol, 12, pp.31~40 (2006)
- Bruno R, "Pharmaco-dynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study", Aliment Pharmacol Ther, 26, pp.369~376 (2007)
- Di Bisceglie AM, "Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C", J Viral Hepat, 14, pp.721~729 (2007)
- Sporea I, "Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis", J Gastrointestin Liver Dis, 15, pp.125~130 (2006)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Bruno R, "Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study", Antivir Ther, 9, pp.491~497 (2004)
- Silva M, "A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterfeon alfa-2a in patients with chronic hepatitis C(COMPARE)", J Hepatol, 45, pp.204~213 (2006)
- Kim KT, "Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C", Korean J Hepatol, 14, pp.36~45 (2008)
- Kuboki M, "Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients", J Gastroenterol Hepatol, 22, pp.645~652 (2007)
- Lee SS, "Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice", Aliment Pharmacol Ther, 23, pp.397~408 (2006)
- Borroni G, "Effectiveness of pegylated interferon", ribavirin combination in ‘real world’ patients with chronic hepatitis C virus infection, 2008, pp.27, 790~797